



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/644,775
				Filing Date	08/21/2003
				First Named Inventor	Tennenbaum
				Art Unit	1647
				Examiner Name	Marianne P. Allen
Sheet	1	of	2	Attorney Docket Number	HEALOR-202

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	6,737,241	05-18-2004	Nolan et al.	
	2	4,940,660	07-10-1990	Hirai	
	3	6,319,907	11-20-2001	Ferguson	
	4	6,582,713	06-24-2003	Newell, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	5	WO 1990/011071 A1	10-04-1990	Dana Farber Cancer Institute		
	6	WO 1993/025660 A1	12-23-1993	Brigham and Women's Hosp.		
	7	WO 2002/072092 A1	09-19-2002	University of Kentucky		
	8	WO 2002/09639	07-07-2002	Tennenbaum, et al.		
	9	WO 2002/017980 A2	03-07-2002	Modex Therapeutics		
	10	WO 2005/007072	01-27-2005	Tennenbaum, et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	11	Al, et al. "The experimental study of bone marrow mesenchymal stem cells on the repair of skin wound combined with local radiation injury", <i>Zhonhghua Yi Xue Za Zhi</i> , 82(23), (2002), pp. 1632-36; Pubmed Abstract PMID 12667374	
	12	ALESSENKO, et al., <i>Biochem. Biophys. Commun.</i> , 182, (1992), pp. 1333-1339	
	13	BAJOU, et al., <i>Nat. Med.</i> , 4 (1998), pp. 923-928	
	14	BANDYOPADHYAY, et al., <i>Biochem. J.</i> , 337 (1999), pp. 461-470	
	15	BENES, et al., <i>Cell</i> , 121 (2005), pp. 271-280	
	16	BRAIMAN, "Protein Kinase C $\delta$ Mediates Insulin-Induced Glucose Transport in Primary Cultures of Rat Skeletal Muscle", <i>Endocrin.</i> , 13(12), pp. 2002-2012	
	17	CHIDA, et al., <i>Mol. Cell Biol.</i> 14 (1994), pp. 3782-90	
	18	DENNING, et al., <i>Cell Growth Differ.</i> , 6 (1995), pp. 149-157	
	19	DLUGOSZ and YUSPA, <i>J. Cell. Biol.</i> , 120 (1993), pp. 217-225	
	20	FORMISANO, et al., <i>J. Biol. Chem.</i> , 273 (1998), pp. 12197-13202	
	21	GSHWENDT, <i>Eur. J. Biochem.</i> , 259 (1999), pp. 555-564	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	<b>10/644,775</b>
				Filing Date	<b>08/21/2003</b>
				First Named Inventor	<b>Tennenbaum</b>
				Art Unit	<b>1647</b>
				Examiner Name	<b>Marianne P. Allen</b>
Sheet	<b>2</b>	of	<b>2</b>	Attorney Docket Number	<b>HEALOR-202</b>

22	HOFMANN, <i>The FASEB J.</i> , 11 (1997), pp. 649-669	
23	MADIBALLY, et al. "Influence of insulin therapy on burn wound healing in rats", <i>J. Surg. Res.</i> , 109 (2003), pp. 92-100.	
24	MISCHAK, et al., <i>J. Biol. Chem.</i> , 268 (1993), pp. 20110-20115	
25	MISCHAK, et al. "Overexpression of Protein Kinase C- $\delta$ and - $\epsilon$ in NIH 3T3 Cells Induces Opposite Effects [...]", <i>J. Biol. Chem.</i> , 268(9), (1993), pp. 6090-96	
26	MOONEY, et al. "Tumor necrosis factor and wound healing", <i>Annals of Surgery</i> , 211 (2), (1990) pp. 124-129	
27	OSADA, et al., <i>J. Biol. Chem.</i> , 265 (1990), pp. 22434-22440	
28	PELLEGRINI, et al. "Cultivation of human keratinocyte stem cells: current and future clinical applications", <i>Med. Biol. Eng. Comp.</i> 36(6), (1998), pp. 778-790	
29	PERLETTI, et al. "Protein Kinase C $\epsilon$ is oncogenic in colon epithelial cells by interaction with the <i>ras</i> signal transduction pathway", <i>Oncogene</i> 16 (1998), pp. 3345-48	
30	REYNOLDS, et al., <i>Br. J. Dermatol.</i> , 133(2), (1995), pp.157-167	
31	RING, et al. "Systematically and topically administered leptin both accelerate wound healing in diabetic <i>ob/ob</i> mice", <i>Endocrin.</i> , 141(1), (2000), pp. 446-449	
32	SERVOLD, et al., "Growth factor impact on wound healing", <i>Clinics in Pod. Med. Surg.</i> , 8(4), (1991), pp. 937-953	
33	SHEN, et al., "Protein Kinase C activation: a divergence point in the signaling of insulin and insulin like growth factor-1 induced proliferation of skin keratinocytes", Bar Ilan Univ., Ramat Gan, Israel (ABSTRACT)	
34	SOLTOFF and TOKER, <i>J. Biol. Chem.</i> , 270 (1995), pp. 13490-13495	
35	SPRAVCHIKOV, et al., "The interactive effects of hyperglycemia, insulin and IGF-1 in murine skin cells - an IR-null mouse model", Dept. of Pathol., Sackler School of Medicine, Tel Aviv Univ., Israel (ABSTRACT)	
36	SUN, et al., <i>Cancer Res.</i> , 52 (1992), pp. 4254-4260	
37	TENNENBAUM, et al., <i>Cell Growth Differ.</i> , 7 (1996), pp. 615-628	
38	WANG, et al., <i>J. Biol. Chem.</i> , 274 (1999), pp. 37233-37239	
39	WERTHEIMER, et al., "The effects of insulin signaling on skin proliferation and differentiation - lessons from the IR- and IRS1 Null Models", Dept. of Pathol., Sackler School of Medicine, Tel Aviv Univ., Israel (ABSTRACT)	
40	WERTHEIMER, et al., <i>J. Invest. Dermatol.</i> , 2000	
41	YUSPA, <i>Cancer Res.</i> , 54 (1994), pp. 1178-1189	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--